| 301 |
22718840 | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. | 2012 Aug 9 |
2 |
| 302 |
22780211 | Emerging targeted therapies in myelofibrosis. | 2012 Jun |
1 |
| 303 |
22830345 | Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. | 2012 |
1 |
| 304 |
22852872 | Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. | 2012 Aug 1 |
1 |
| 305 |
22899477 | Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. | 2012 Aug 16 |
2 |
| 306 |
23051187 | Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. | 2012 Nov |
3 |
| 307 |
23186315 | Emerging drugs for myelofibrosis. | 2012 Dec |
1 |
| 308 |
23238141 | Janus activated kinase inhibition in myelofibrosis. | 2012 Jul-Sep |
2 |
| 309 |
27175229 | Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. | 2012 May |
1 |
| 310 |
21079613 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. | 2011 Feb |
1 |
| 311 |
21635221 | A potential role of ruxolitinib in leukemia. | 2011 Aug |
2 |
| 312 |
21677670 | Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. | 2011 Sep |
1 |
| 313 |
22034658 | Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. | 2011 Dec |
2 |
| 314 |
22146225 | Ruxolitinib for the treatment of myelofibrosis. | 2011 Nov |
3 |
| 315 |
22362131 | Clinical and laboratory features of myelofibrosis and limitations of current therapies. | 2011 Sep |
1 |
| 316 |
20506062 | Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. | 2010 Jun |
4 |
| 317 |
20843246 | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. | 2010 Sep 16 |
1 |
| 318 |
19468275 | Novel strategies for patients with chronic myeloproliferative disorders. | 2009 Mar |
2 |
| 319 |
19552608 | Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. | 2009 Sep |
1 |